Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

VCYT - VERACYTE, INC.

IEX Last Trade
40.07
0.020   0.050%

Share volume: 12,589
Last Updated: Fri 27 Dec 2024 08:30:07 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%
$40.05
0.02
0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
9%
Profitability 0%
Dept financing 2%
Liquidity 72%
Performance 4%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.10%
1 Month
-4.52%
3 Months
21.26%
6 Months
86.22%
1 Year
44.04%
2 Year
71.55%
Key data
Stock price
$40.07
P/E Ratio 
-44.84
DAY RANGE
$39.76 - $40.84
EPS 
-$0.73
52 WEEK RANGE
$19.19 - $46.00
52 WEEK CHANGE
$48.85
MARKET CAP 
2.423 B
YIELD 
N/A
SHARES OUTSTANDING 
76.812 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
BETA 
1.94
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$767,212
AVERAGE 30 VOLUME 
$743,723
Company detail
CEO: Marc A. Stapley
Region: US
Website: veracyte.com
Employees: 790
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas. It is also developing Percepta Genome Atlas to help inform lung cancer treatment decisions.

Recent news